Continued Elevation of Plasma IL-4 and IL-17 Predicts the Progression from VMC to DCM
Table 4
Longitudinal change of IFN-γ, IL-4, and IL-17 (pg/ml) levels in VMC patients with the incident of DCM.
Without DCM ()
With DCM ()
value
Median
1st quartile
3rd quartile
Median
1st quartile
3rd quartile
IFN-γ
Baseline
76.5
11.0
105.6
97.0
80.7
122.6
0.0165
1st month
79.4
18.8
116.8
137.4
109.7
161.8
<.0001
3rd month
77.6
12.3
115.0
173.9
126.5
204.7
<.0001
for trend
0.1334
<.0001
IL-4
Baseline
38.35
21.05
56.57
84.25
59.2
103.74
<0.0001
Visit 1 (1st month)
34.04
19.1
55.35
92.3
64.85
113.65
<0.0001
Visit 2 (3rd month)
27.3
17.15
53.58
113.04
79.43
139.19
<0.0001
for trend
0.5157
<0.0001
IL-17
Baseline
19.32
12.63
24.72
38.81
30.42
50.42
<0.0001
Visit 1 (1st month)
18.06
12.55
20.64
43.67
37.25
50.1
<0.0001
Visit 2 (3rd month)
16.9
12.67
19.16
51.68
44.08
59.27
<0.0001
for trend
0.1348
0.0235
Data are expressed as median (1st Quartile-3rd Quartile). for trend means the mixed-effect model. Detecting three times for the sample deciding if there is longitudinal change or not.
